Pfizer began construction on a more than $200-million, 5-story, 175,000 square foot biologics clinical manufacturing plant in Andover, Massachusetts. The facility, which will be used to manufacture complex biologics and vaccines, is projected to open by January 2019.
“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, Senior Vice President, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”
Earlier this year, Andover officials approved $2.9 million in tax incentives for the Pfizer project. The town’s Board of Selectmen, Planning Board and Finance Committee all recommended the five-year Tax-Increment Financing plan.
“Pfizer’s decision to expand their campus in Andover speaks to the Commonwealth’s continued global leadership in biopharma and our administration’s support of the growing advanced manufacturing sector,” said Massachusetts’ Lieutenant Governor Karyn Polito. “We are pleased to have Pfizer operating in Andover, Boston and Cambridge and look forward to their ongoing contributions to the Massachusetts’s economy and wellbeing of our citizens.”